Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

Publisher： Karger

E-ISSN： 1661-7657|9|1|31-35

ISSN： 1661-7649

Source： Current Urology, Vol.9, Iss.1, 2015-0, pp. : 31-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

By  

Urologia Internationalis, Vol. 77, Iss. 2, 2006-08 ,pp. : 135-138

Karger

Access to resources Recommend Favorite

Non‐steroidal antiandrogen monotherapy compared with luteinizing hormone‐releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review

By  

BJU INTERNATIONAL, Vol. 116, Iss. 1, 2015-07 ,pp. : 30-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients

By  

Urologia Internationalis, Vol. 82, Iss. 3, 2009-05 ,pp. : 249-255

Karger

Access to resources Recommend Favorite

Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 135-139

Karger

Access to resources Recommend Favorite

The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen deprivation therapy

By  

THE PROSTATE, Vol. 75, Iss. 14, 2015-10 ,pp. : 1499-1509

John Wiley & Sons Inc

Access to resources Recommend Favorite